文献速递肝病

新型细胞内蛋白CREG抑制肝脂肪变性、肥胖和胰岛素抵抗

The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance.
PubMed 文献 · Hepatology · 2017-07-31

本研究探讨CREG在代谢紊乱和肝脂肪变性中的作用及机制。肝细胞特异性CREG缺失加重高脂饮食和瘦素缺乏诱导的肥胖、肝脂肪变性和代谢紊乱,而CREG过表达有益;机制上CREG直接与ASK1相互作用并抑制其磷酸化,阻断下游MKK4/7-JNK1信号通路;NAFLD患者肝脏中CREG表达显著降低且JNK1信号过度激活。

要点

  • 肝细胞特异性CREG缺失加重高脂饮食和ob/ob诱导的肥胖、肝脂肪变性和代谢紊乱,CREG过表达则有益。
  • JNK1而非JNK2介导CREG的保护作用,抑制JNK1可阻止CREG缺失的不良效应。
  • CREG直接与ASK1结合并抑制其磷酸化,阻断MKK4/7-JNK1通路,减轻肥胖、胰岛素抵抗和肝脂肪变性。

核心结论

  • CREG通过与ASK1直接相互作用并使ASK1-JNK1信号失活,是肝脂肪变性和代谢紊乱的强效抑制因子。
  • NAFLD患者肝脏中CREG表达显著降低且JNK1信号过度激活,提示CREG可能是NAFLD及相关代谢病的有希望的治疗靶点。

研究设计与样本

  • 基础与转化研究,采用肝细胞特异性CREG缺失和CREG过表达模型,观察高脂饮食和瘦素缺乏(ob/ob)诱导的肥胖、肝脂肪变性和代谢紊乱。
  • 进一步实验探讨JNK1与JNK2在CREG保护效应中的作用,并检测NAFLD患者肝脏中CREG表达和JNK1信号。

主要发现

  • 肝细胞特异性CREG缺失显著加重高脂饮食和ob/ob诱导的肥胖、肝脂肪变性和代谢紊乱,而CREG过表达产生有益效应。
  • JNK1而非JNK2在很大程度上介导CREG对上述病理的保护作用,抑制JNK1可强效阻止CREG缺失对脂肪变性和相关代谢紊乱的不良影响。
  • CREG直接与ASK1相互作用并抑制其磷酸化,阻断下游MKK4/7-JNK1信号通路,显著减轻肥胖、胰岛素抵抗和肝脂肪变性。
  • NAFLD患者肝脏中观察到CREG表达显著降低且JNK1信号过度激活。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Cellular repressor of E1A-stimulated genes (CREG), a novel cellular glycoprotein, has been identified as a suppressor of various cardiovascular diseases because of its capacity to reduce hyperplasia, maintain vascular homeostasis, and promote endothelial restoration. However, the effects and mechanism of CREG in metabolic disorder and hepatic steatosis remain unknown. Here, we report that hepatocyte-specific CREG deletion dramatically exacerbates high-fat diet and leptin deficiency-induced (ob/ob) adverse effects such as obesity, hepatic steatosis, and metabolic disorders, whereas a beneficial effect is conferred by CREG overexpression. Additional experiments demonstrated that c-Jun N-terminal kinase 1 (JNK1) but not JNK2 is largely responsible for the protective effect of CREG on the aforementioned pathologies. Notably, JNK1 inhibition strongly prevents the adverse effects of CREG deletion on steatosis and related metabolic disorders. Mechanistically, CREG interacts directly with apoptosis signal-regulating kinase 1 (ASK1) and inhibits its phosphorylation, thereby blocking the downstream MKK4/7-JNK1 signaling pathway and leading to significantly alleviated obesity, insulin resistance, and hepatic steatosis. Importantly, dramatically reduced CREG expression and hyperactivated JNK1 signaling was observed in the livers of nonalcoholic fatty liver disease (NAFLD) patients, suggesting that CREG might be a promising therapeutic target for NAFLD and related metabolic diseases. CONCLUSION: The results of our study provides evidence that CREG is a robust suppressor of hepatic steatosis and metabolic disorders through its direct interaction with ASK1 and the resultant inactivation of ASK1-JNK1 signaling. This study offers insights into NAFLD pathogenesis and its complicated pathologies, such as obesity and insulin resistance, and paves the way for disease treatment through targeting CREG. (Hepatology 2017;66:834-854).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zhang QY, Zhao LP, Tian XX, et al. The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance. Hepatology. 2017. PMID: 28508477. doi:10.1002/hep.29257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。